RRG001
Phase 2Small molecule
RRG001 is one of 42 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Zometa
PfizerApproved
Bayer Aspirin
BayerApproved
Tecfidera
BiogenApproved
Plavix
SanofiApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Proliferative Diabetic Retinopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RRG001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- LLi Xiaorong